Welcome to our dedicated page for Cytomx Therapeutics SEC filings (Ticker: CTMX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking R&D swings at a clinical-stage biotech is hard enough—doing it inside CytomX Therapeutics’ two-hundred-plus-page reports can feel impossible. If you have ever typed “Where can I find the CytomX Therapeutics quarterly earnings report 10-Q filing?” or “How do I monitor CytomX Therapeutics insider trading Form 4 transactions?”, you already know the challenge. Stock Titan turns that complexity into clarity, with CytomX Therapeutics SEC filings explained simply.
Our AI reads every submission the moment it lands on EDGAR, then delivers plain-English takeaways you can trust. Need the CytomX Therapeutics annual report 10-K simplified? Prefer the CytomX Therapeutics 8-K material events explained in one paragraph? Looking for the CytomX Therapeutics proxy statement executive compensation table without scrolling? It’s all here—plus real-time alerts that flag CytomX Therapeutics Form 4 insider transactions right as they post.
Because CytomX relies on milestone payments and collaboration revenue, a single footnote can shift valuation models overnight. Stock Titan’s AI highlights those footnotes, compares cash-burn trends, and links trial updates across quarters so you don’t miss a beat. Use the platform to:
- Compare R&D expense paths quarter-over-quarter through CytomX Therapeutics earnings report filing analysis
- Track leadership equity grants via CytomX Therapeutics executive stock transactions Form 4
- Receive push notifications on CytomX Therapeutics Form 4 insider transactions real-time
- Download clean tables for valuation and diligence models
Understanding CytomX Therapeutics SEC documents with AI means spending minutes—not hours—on the disclosures that drive this pioneering probody technology developer.
Biotechnology Value Fund (BVF) and related entities have filed Amendment No. 5 to Schedule 13G for CytomX Therapeutics, Inc. (CTMX). As of the close of business on 9 July 2025, the group collectively holds 5,769,231 common-share equivalents in the form of Tranche 2 warrants that are exercisable at $3.77 per share and expire on 3 July 2026. The warrants include a 9.99 % beneficial-ownership blocker that limits exercise to keep the holder’s ownership below that threshold.
Beneficial ownership is reported on a disaggregated basis: BVF (3.07 M shares; 1.9 %), BVF II (2.35 M; 1.5 %), and Biotechnology Value Trading Fund OS (0.27 M; <1 %). Through control relationships, BVF GP Holdings and BVF Partners L.P. may be deemed to beneficially own 3.3 % and 3.5 % of outstanding shares, respectively. All entities disclaim ultimate beneficial ownership beyond their respective capacities.
The percentages are calculated against a base of 157.54 M common shares outstanding following the issuer’s May 2025 equity offering, plus the warrants counted as if exercised. No holder exceeds the 5 % reporting threshold individually, and the filing is made on Schedule 13G to reflect passive investment intent; the certification confirms the securities were not acquired to influence control of CTMX.
Key takeaways for investors
- BVF remains a notable but non-controlling holder with a ~3.5 % aggregate economic interest.
- Exposure is entirely via $3.77 warrants, providing potential upside without current voting power.
- The 9.99 % blocker limits near-term ownership expansion but allows full exercise should total shares outstanding rise.
- The amendment updates ownership levels following the issuer’s recent public offering and does not signal activism.
Biotechnology Value Fund (BVF) and affiliated entities have filed Amendment 4 to a Schedule 13G disclosing their aggregate beneficial ownership of CytomX Therapeutics, Inc. (NASDAQ: CTMX) as of 30 June 2025.
The filing shows that the BVF complex—comprising eight Delaware and Cayman-based funds and general partners plus founder Mark N. Lampert—collectively controls 11,538,462 common shares, or 6.8 % of CytomX’s outstanding stock. The position is held entirely through two series of cash-settled warrants:
- Tranche 1 Warrants: 5,769,231 shares, strike $2.73, expire 3 July 2025.
- Tranche 2 Warrants: 5,769,231 shares, strike $3.77, expire 3 July 2026.
The warrants are subject to a 9.99 % “blocker,” preventing exercise that would take the group’s ownership above that threshold. Current ownership remains below 7 %, therefore none of the warrants are blocked.
Breakdown of key subsidiary holdings:
- Biotechnology Value Fund L.P.: 6,148,026 shares (3.8 % of class)
- Biotechnology Value Fund II L.P.: 4,702,892 shares (2.9 % of class)
- Biotechnology Value Trading Fund OS LP: 541,232 shares (<1 % of class)
BVF GP Holdings LLC (6.4 %) and BVF Partners L.P. (6.8 %) are the primary control entities, with shared voting and dispositive power across the structure. All parties certify the stake is passive and not intended to influence control of CytomX.
The ownership percentages are calculated against 157,544,369 shares reported outstanding in CytomX’s May 13 2025 prospectus plus the warrant shares, where applicable.